Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated w1ith pneumococcal polysaccharide vaccine

Marshall J. Glesby, Wendy Watson, Cynthia Brinson, Richard N. Greenberg, Jacob P. Lalezari, Daniel Skiest, Vani Sundaraiyer, Robert Natuk, Alejandra Gurtman, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmoele-Thoma

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Persons with human immunodeficiency virus (HIV) infection are at increased risk of pneumococcal disease. We evaluated the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) in this population. Methods. HIV-infected persons ≥18 years of age who were previously vaccinated with ≥1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4 cell counts ≥200 cells/mm3 and HIV viral loads <50 000 copies/mL were enrolled in this 3-dose PCV13 open-label study. Results. A total of 329 subjects received ≥1 dose, and 279 received 3 doses administered at 6-month intervals. Increases in anticapsular polysaccharide immunoglobulin G concentrations and opsonophagocytic antibody titers were demonstrated 1 month after each of the 3 doses of PCV13. Antibody levels were generally similar after each dose. The responses were similar whether subjects had previously received 1 or ≥2 doses of PPSV23. Pain at the injection-site was the most common local reaction. Severe injection site or systemic events were uncommon. Conclusions. Vaccination with PCV13 induces anticapsular immunoglobulin G and opsonophagocytic antibody responses in HIV-infected adults with prior PPSV23 vaccination and CD4 cell counts ≥200 cells/mm3. The observations support the use of PCV13 in this population.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalJournal of Infectious Diseases
Volume212
Issue number1
DOIs
StatePublished - Jul 1 2015

Bibliographical note

Publisher Copyright:
© 2014 The Author.

Keywords

  • Human immunodeficiency virus
  • adult
  • immunogenicity
  • pneumococcal conjugate vaccine
  • pneumococcal polysaccharide vaccine.

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated w1ith pneumococcal polysaccharide vaccine'. Together they form a unique fingerprint.

Cite this